We are pleased to announce that The Children's Memorial Health Institute in Warsaw, Poland is purchasing DrugLog. Medim is our first customer for DrugLog, which we acquired at the beginning of the year to complement our existing product offering. DrugLog represents a further step towards the vision of providing software support for all types of cancer treatments, including chemotherapy and surgery.

This is an important milestone for our partnership with RaySearch. The new customer is a proof of how our joint efforts and expertise create concrete results in the market.

The start of proton arc treatments marks a major milestone in proton therapy, and it has been great to see the commitment of the team at the Trento Proton Therapy Center in introducing the technique into their clinical workflow. I am proud that RaySearch has played an instrumental role in pioneering proton arc therapy by advanced optimization algorithms and planning tools.

In the same way as VMAT has revolutionized radiotherapy with photons, proton arc treatments have the potential to unlock significant additional benefits in proton therapy, taking it to the next level in several clinical indications The collaboration between radiation oncologists, medical physicists, and RaySearch has been the key to this progress in delivery technique.

I am very much looking forward to meeting both existing and new customers at RSNA and presenting the exciting research results regarding liver ablation and our product portfolio, including DrugLog which represents an expansion of our offering, outside of radiation therapy.

Advanced key tools available in the RaySearch environment will help us bring our proton treatments to the highest quality.

We are proud of our collaboration with Institut Curie, a well-reputed hospital with an impressive legacy. The agreement is a first step; I look forward to deepening our relationship and to a fruitful collaboration.

I am very happy to welcome Nina to the position as CFO of RaySearch. With her extensive experience in finance and strong leadership skills, I am confident that she will play a key role in driving the company's continued growth.

RaySearch is an innovative company and a driving force in the fight against cancer. The finance function has an important role to play in this exciting phase of expansion that RaySearch is currently undergoing.

I am very happy about the agreements with these important French centers, especially since they are all comprehensive cancer centers. RayStation is an excellent starting point, but our vision is that our software should support all the disciplines included in a comprehensive cancer center.

We are very happy about our first RayStation order from the prestigious China Japan Friendship Hospital in Beijing. The fact that we now also have more than 100 customers in China is an important step in our continued expansion in the Chinese market, where we see great potential to improve cancer care with RayStation and our other technologies.

We are pleased to announce an order from GenesisCare UK. RayStation is well-equipped for this network's requirements for remote planning and optimal workload distribution. I am convinced that RayStation will pave the way for efficient patient treatments and further contribute to GenesisCare’s pursuit of the highest possible standard.

Our vision is to redefine the standard of cancer care with passion, innovation and a unique national network of the best. Within this vision is our roadmap to continually strive for higher standards in treatment quality and extend GenesisCare’s adaptive therapy services across multiple treatment platforms. We are excited to announce we have been able to include the RayStation treatment planning system within our portfolio of planning solutions, supporting our provision of high quality, robust radiotherapy treatments, with particular benefit for patients with some of the most challenging and complex cases.

We are excited to return to ASTRO in Washington, meeting valued partners as well as customers and potential customers. We are also eager to showcase our latest product innovations to attendees joining us in our booth.

My team and I are extremely happy to have been part of the journey of developing RayCare to what it is today, a next generation oncology information system designed to incorporate all disciplines of cancer care. We aspire to create one oncology workflow, allowing a seamless experience for both patients and health care professionals.

With RayCare we achieve consistency and automation, two factors that play a crucial role in maintaining patient safety, efficiency and quality of care. RayCare strongly contributes to our ability to offer cutting-edge radiation oncology solutions to patients throughout our network.

RayCare is the result of a strong partnership between industry and clinical experts in developing an integrated oncology information system and I am proud of our long-standing collaboration with Iridium Network. Today, when RayCare was connected with TrueBeam, an important milestone was clinically manifested for our shared commitment to advancing cancer care with the patient in focus.

We are happy to welcome yet another RayCare customer. For our installed base of RayStation customers the selection of RayCare as oncology information system will enhance efficiency and user experience, both in the treatment planning process and treatment delivery.

In the second quarter of 2024, net sales rose by 33 percent. Revenue from support rose by 12,9 percent. Operating profit amounted to SEK 79.3 M (18.2) in the second quarter and to SEK 125.1 M (41.9) for the first half-year.

As always on the AAPM congress I anticipate fruitful discussions with both clinical and industry partners as well as current and potential customers. In particular, I am looking forward to discussing the excellent experiences our customers will have utilizing RayCare with the Varian TrueBeam family of linear accelerators.

Automation of repetitive tasks is essential to boost the efficiency at the clinics. This efficiency gain will be important to be able to serve an increasing patient population to be treated for cancer, as well as to free up time to handle the more complicated patient cases. I am proud that RaySearch leads the way in this transition.

NYPC and its consortium have been excellent to work with. The team at NYPC is among the world leaders in the proton field, and it is especially gratifying that their decision to more fully transition to RayStation was based on extensive assessment of our products and service at all levels. We also look forward to working with NYPC and collaborating well into the future.

We worked very hard over the last two years to assess the technologies in RayStation and how it could help us provide the best possible plans for our patients, utilizing the most advanced features available to us as clinicians. We are pleased that we are now able to transition even more treatment planning to RayStation.

Moving to a new treatment planning platform is a large task, both technically as well as financially. NYPC is glad to partner with RaySearch, who helped us demonstrate that we could plan faster, smarter and more efficiently, and even shorten treatment times for some patients. We look forward to a long collaboration.

As we celebrate 10 years of defining state-of-the-art proton therapy treatment planning, we continue to focus on continuous innovation in particle therapy treatment planning software. We constantly push boundaries to help clinics achieve the best patient outcomes.

We know that RayCare receives positive reviews in technical evaluations of different types of oncology information systems. With its advanced functionality, which has been further improved in the latest version, combined with the interoperability with TrueBeam, RayCare now represents a very attractive alternative to competing systems, which is confirmed by both new and existing customers. One example, that we previously informed about, is Raigmore Hospital in Scotland. Their radiotherapy center has used RayStation for their TrueBeam linear accelerators for many years and recently decided to replace their existing oncology information system with RayCare. I am confident that more centers will make similar shifts from older oncology information systems to RayCare going forward.

In the first quarter of 2024, net sales rose by 12 percent. Revenue from support rose by 23 percent. Operating profit amounted to SEK 45.8 M (23.7) in the first quarter.

Interoperability with treatment delivery systems is a key feature of RayCare and it is gratifying to see that the interoperability of the latest version of RayCare with TrueBeam has been achieved in time for the release and I look forward to clinical implementation of the connection later in 2024.

By achieving clinical interoperability between TrueBeam and RayCare, Varian again shows our commitment to developing, deploying, and maintaining critical interfaces for our fleet to operate seamlessly. RaySearch as an alliance in our ecosystem program is another example of our resolve to meet the diverse needs of customers across the world.

We are thrilled about the collaboration with RaySearch, where we will enhance and find new innovative solutions in our common fight against cancer.

I look forward to collaborating with C-RAD, which is also located close to us in Sweden. The additional information about the patient’s anatomy provided by surface scanning from Catalyst+ has the potential to greatly improve different steps in the radiation therapy treatment planning process in RayStation.

Our installed base of RayCare customers is steadily increasing and I am happy to welcome Raigmore Hospital as a new RayCare customer. I am impressed by the center’s efficient use of RayStation and the fact that they now have selected RayCare will further improve their efficiency. I am looking forward to working with the team at Raigmore Hospital for a smooth transition.

We have used RayStation since 2016 and look forward to the introduction of RayCare to the department. As well as the improved integration with RayStation that it will provide, we were impressed with the automation of tasks which has the potential to improve the workflows. The possibility of using scripting as we do in RayStation further enhances this ability. We also see great potential to improve the communication and documentation which is currently fragmented across a number of different systems.

We look forward to continuing our long and close collaboration with QST, to bring new solutions with speed, efficiency and optimization to healthcare providers around the world who are at the forefront of fighting cancer.

We are very pleased to have RayStation which will expand our research capabilities and also improve our ability to treat patients with high precision.

In the fourth quarter of 2023, net sales rose by 13 percent. Revenue from support rose by 40 percent. Operating profit amounted to SEK 44.4 M (20.7) in the fourth quarter and to SEK 114.9 M (42.7) for the full year.

"We are excited to welcome DrugLog to RaySearch's product portfolio. Since its inception, RaySearch has focused on software for optimizing and planning radiation therapy. However, the long-term vision is to provide software support for all types of cancer treatments, including chemotherapy and surgery. As a first step, we intend to add support for treatment planning in RayStation and workflows in RayCare for chemotherapy management. We anticipate that these extensions will be launched by 2026 at the latest. DrugLog will be an excellent complement to this and significantly improve and simplify quality assurance in cancer treatment with chemotherapy. We look forward to integrating DrugLog into our offering and continuing to deliver innovative solutions to cancer centers worldwide."

I am a strong believer of the clinical benefits of adaptive radiation therapy. The tools have been available in RayStation for many years and RayCare has from the beginning been developed to facilitate the implementation of OART in clinical routine. In ARTemis we will have a very strong solution to enable online adaptive and I could not have asked for a better partner than The Royal Marsden, with which we have an established and fruitful collaboration, to be the pioneering center for this exciting new solution.

This is an important milestone for RaySearch. We have invested significant resources in developing the by far most advanced treatment planning system, with support for almost all available treatment machines. Today, we see that our efforts have paid off with over 1,000 centers who have purchased RayStation. I also note with pride that ten of the fifteen highest ranked cancer hospitals in the world, according to a ranking by Newsweek, are current customers of ours. This reflects our strong position also in the top segment and confirms RaySearch as a leading vendor of high-quality cancer treatment.

The Froedtert & MCW health network is an excellent example of the kind of health system that will enjoy the maximum benefit from RaySearch's technologies. RayStation's support for multiple delivery systems makes implementation easier and more effective at many levels. The medical staff will be able to use a single platform and determine the ideal treatment modality for every cancer patient. We look forward to working with the Froedtert & MCW cancer team for many years to come.

Further enhancing the capabilities of multi-modality treatments is key for RaySearch in the ambition to provide tools to create the best treatment plans for cancer patients. With RayStation 2024A we also continue with improvements within fast adaptive re-planning, which will be an important focus area during the coming years.

Online adaptive has been a key focus for RaySearch for many years and I am impressed by the work that is done at Vejle. RayStation has very advanced tools available for taking online adaptive into clinical routine and the work done by Vejle is showcasing what groundbreakning possibilities our users have to further advance cancer treatments.

We are dedicated to pushing the boundaries of innovation for improved patient care and operational excellence. Our goal with the new workflow is to significantly reduce the time that a patient undergoing short-course palliative radiotherapy has to stay in the hospital.

In the third quarter of 2023, net sales rose by 20 percent. Revenue from support rose by 23 percent. Operating profit amounted to SEK 28.6 M (12.0) in the third quarter and to SEK 70.5 M (22.0) for the first nine months.

I am greatly encouraged that OHSU will integrate RayStation with Radixact, marking another step forward in our commitment to advancing radiation technology. This collaboration broadens the availability of our innovative solutions, ultimately enhancing the quality of care for cancer patients.

We are happy to add these centers to our growing installed base. The strategy for RaySearch has from the beginning been to support virtually all commercially available machines. Right now, RayStation is the only treatment planning system available that can facilitate a unified workflow for such large and diversified centers as Baptist Health Lexington and Baptist Health Hamburg and we are looking forward to a successful collaboration.

Mass General is truly a pioneering collaboration partner to RaySearch. They were one of the very first users of RayStation in the world and we have benefitted greatly from various collaboration projects that we have done together during the years. I am happy that they now have the opportunity to start using RayStation also for their proton treatments.

RaySearch’s expertise in oncology software and Mevion Medical Systems’ latest technological advancements will continue to bring innovation in the proton therapy field and we look forward to working together with Mevion to further advance proton cancer treatments.

The synergy between Mevion Medical Systems and RaySearch Laboratories continues to redefine the landscape of cancer care. The united strength of our collaborative partnership is accelerating the deployment of emerging proton therapy developments. We are committed to breaking down technological and clinical access barriers to superior proton therapy technology.

PSI is an exceptional place to treat cancer, and I am proud to welcome them as customers. It is also very exciting to engage in several research projects together with a partner with such strong research capabilities. This will be beneficial for the next generation of RayStation as well as an important step in fulfilling our vision of a world where cancer is conquered.